EMA Panel Backs Fostamatinib (Tavalisse) for Chronic ITP EMA Panel Backs Fostamatinib (Tavalisse) for Chronic ITP

Fostamatinib, a spleen tyrosine kinase inhibitor, helps increase and maintain the platelet count and reduce bleeding risk in adults with chronic immune thrombocytopenia refractory to other treatments.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news